文献速递胸部肿瘤

特泊替尼治疗MET外显子14跳跃突变非小细胞肺癌患者:VISION 2期非随机临床试验长期随访

Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

VISION 2期非随机试验评估特泊替尼500 mg每日一次治疗MET外显子14跳跃突变晚期/转移性非小细胞肺癌的长期疗效与安全性,A和C队列共313例。总客观缓解率51.4%,中位缓解持续时间18.0个月;初治患者客观缓解率57.3%,经治患者45.0%。外周水肿最常见(67.1%),≥3级占11.2%。

要点

  • A和C队列共313例,客观缓解率51.4%,中位缓解持续时间18.0个月。
  • 初治患者(n=164)客观缓解率57.3%,中位缓解持续时间46.4个月。
  • 经治患者(n=149)客观缓解率45.0%,中位缓解持续时间12.6个月。

核心结论

  • C队列结果支持原A队列结果,VISION长期结局显示特泊替尼在MET外显子14跳跃突变非小细胞肺癌中具有稳健且持久的临床活性,尤其在初治患者中。

研究设计与样本

  • VISION为2期非随机临床试验,多队列、开放标签、多中心设计,纳入MET外显子14跳跃突变晚期/转移性非小细胞肺癌患者(A和C队列)。
  • 入组时间为2016年9月至2021年5月,数据截止日期为2022年11月20日。
  • C队列(随访>18个月)为独立队列,用于确认A队列(随访>35个月)的发现。
  • 患者接受特泊替尼500 mg(450 mg活性部分)每日一次口服。
  • 主要终点为独立审查委员会评估的客观缓解(RECIST v1.1)。

主要发现

  • A和C队列共313例患者,女性占50.8%,亚洲人占33.9%,中位年龄72岁(范围41-94岁)。
  • 总体客观缓解率为51.4%(95% CI,45.8%-57.1%),中位缓解持续时间为18.0个月(95% CI,12.4-46.4)。
  • C队列(n=161)跨治疗线客观缓解率为55.9%(95% CI,47.9%-63.7%),中位缓解持续时间为20.8个月(95% CI,12.6-不可估计[NE]),与A队列(n=152)相当。
  • 初治患者(A和C队列,n=164)客观缓解率为57.3%(95% CI,49.4%-65.0%),中位缓解持续时间为46.4个月(95% CI,13.8-NE)。
  • 经治患者(n=149)客观缓解率为45.0%(95% CI,36.8%-53.3%),中位缓解持续时间为12.6个月(95% CI,9.5-18.5)。

关键数值与推荐

  • 总体客观缓解率51.4%(95% CI,45.8%-57.1%),中位缓解持续时间18.0个月(95% CI,12.4-46.4)。
  • C队列客观缓解率55.9%(95% CI,47.9%-63.7%),中位缓解持续时间20.8个月(95% CI,12.6-NE)。
  • 初治患者客观缓解率57.3%(95% CI,49.4%-65.0%),中位缓解持续时间46.4个月(95% CI,13.8-NE)。
  • 经治患者客观缓解率45.0%(95% CI,36.8%-53.3%),中位缓解持续时间12.6个月(95% CI,9.5-18.5)。
  • 外周水肿发生210例(67.1%),其中35例(11.2%)为≥3级。

临床怎么用

  • 作者指出,VISION长期结局支持特泊替尼的全球获批,并使临床医生能够为此类患者实施该治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 (METex14)-skipping non-small cell lung cancer (NSCLC); however, data with longer follow-up and in larger populations are needed to further optimize therapeutic approaches. OBJECTIVE: To assess the long-term efficacy and safety of tepotinib, a potent and highly selective MET inhibitor, in patients with METex14-skipping NSCLC in the VISION study. DESIGN, SETTING, AND PARTICIPANTS: The VISION phase 2 nonrandomized clinical trial was a multicohort, open-label, multicenter study that enrolled patients with METex14-skipping advanced/metastatic NSCLC (cohorts A and C) from September 2016 to May 2021. Cohort C (>18 months' follow-up) was an independent cohort, designed to confirm findings from cohort A (>35 months' follow-up). Data cutoff was November 20, 2022. INTERVENTION: Patients received tepotinib, 500 mg (450 mg active moiety), once daily. MAIN OUTCOMES AND MEASURES: The primary end point was objective response by independent review committee (RECIST v1.1). Secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Cohorts A and C included 313 patients (50.8% female, 33.9% Asian; median [range] age, 72 [41-94] years). The objective response rate (ORR) was 51.4% (95% CI, 45.8%-57.1%) with a median (m)DOR of 18.0 (95% CI, 12.4-46.4) months. In cohort C (n = 161), an ORR of 55.9% (95% CI, 47.9%-63.7%) with an mDOR of 20.8 (95% CI, 12.6-not estimable [NE]) months was reported across treatment lines, comparable to cohort A (n = 152). In treatment-naive patients (cohorts A and C; n = 164), ORR was 57.3% (95% CI, 49.4%-65.0%) and mDOR was 46.4 (95% CI, 13.8-NE) months. In previously treated patients (n = 149), ORR was 45.0% (95% CI, 36.8%-53.3%) and mDOR was 12.6 (95% CI, 9.5-18.5) months. Peripheral edema, the most common treatment-related adverse event, occurred in 210 patients (67.1%) (35 [11.2%] experienced grade ≥3 events). CONCLUSIONS AND RELEVANCE: The findings from cohort C in this nonrandomized clinical trial supported the results from original cohort A. Overall, the long-term outcomes of VISION demonstrated robust and durable clinical activity following treatment with tepotinib, particularly in the treatment-naive setting, in the largest known clinical trial of patients with METex14-skipping NSCLC, supporting the global approvals of tepotinib and enabling clinicians to implement this therapeutic approach for such patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02864992.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mazieres J, Paik PK, Garassino MC, et al. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2023. PMID: 37270698. doi:10.1001/jamaoncol.2023.1962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。